Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer

• DOI: 10.1126/science.aak9510
• Publication Date: 2017-04-13T17:55:16Z
• Authors: Sanja Stevanović; Anna Pasetto; Sarah R. Helman; Jared J. Gartner; Todd D. Prickett; Bryan Howie; Harlan S. Robins; Paul F. Robbins; Christopher A. Kl...; Steven A. Rosenberg; Christian S. Hinr...
• Keywords: 0301 basic medicine; Human papillomavirus 16; Human papillomavirus 18; T-Lymphocytes; Papillomavirus Infections; Programmed Cell Death 1 Receptor; Uterine Cervical Neoplasms; Oncogene Proteins, Viral; Immunotherapy, Adoptive; 3. Good health; DNA-Binding Proteins; Repressor Proteins; 03 medical and health sciences; Lymphocytes, Tumor-Infiltrating; Antigens, Neoplasm; Carcinoma, Squamous Cell; Humans; Female

Targeting nonviral antigens in viral-driven cancer

Adoptive cell transfer harnesses a patient's own T cells to destroy cancer. The strategy can successfully treat epithelial tumors driven by human papillomavirus (HPV), but it remains unclear why only some patients respond. Stevanović et al. examined the antitumor T cell response associated with HPV + cervical cancers that underwent complete regression. Unexpectedly, reactive T cells were not directed against virally associated antigens, but rather against cancer germline antigens or neoantigens not previously recognized by the immune system. These findings counter the widely held belief that T cell responses against viral antigens are responsible for therapeutic effects in HPV-driven cancers.

Science , this issue p. 200